21012-18-0

Basic information

• Product Name: BOC-3-(1-PYRAZOLYL)-ALA-OH
• Synonyms: (S)-2-(Boc-amino)-3-(1-pyrazolyl)propionic acid, Nα-Boc-3-(1-pyrazolyl)-L-alanine;Boc-3-(1-Pyrazolyl)-L-alanine;Nα-Boc-3-(1-pyrazolyl)-L-alanine;1H-Pyrazole-1-propanoic acid, .alpha.-[[(1,1-dimethylethoxy)carbonyl]amino]-, (.alpha.S)-;N-Boc-3-(Pyrazol-1-yl)-L-alanine;Boc-3-(Pyrazol-1-yl)-L-Ala-OH
• CAS NO: 21012-18-0
• Molecular Formula: C₁₁H₁₇N₃O₄
• Molecular Weight: 255.272
• Product Categories: amino acids
• Mol File: 21012-18-0.mol

Chemical Properties

• Boiling Point: 441.942°C at 760 mmHg
• Flash Point: 221.079°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BOC-3-(1-PYRAZOLYL)-ALA-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-3-(1-PYRAZOLYL)-ALA-OH(21012-18-0)
• EPA Substance Registry System: BOC-3-(1-PYRAZOLYL)-ALA-OH(21012-18-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 21012-18-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BOC-3-(1-PYRAZOLYL)-ALA-OH is used as a building block in peptide synthesis for the development of pharmaceuticals. Its unique structure allows for the creation of peptides with specific properties, which can be utilized in the treatment of various diseases and conditions.
Used in Research Applications:
In the field of research, BOC-3-(1-PYRAZOLYL)-ALA-OH is used as a component in the synthesis of peptides for studying their biological activities and potential therapeutic effects. BOC-3-(1-PYRAZOLYL)-ALA-OH's versatility in peptide synthesis makes it a valuable tool for exploring new drug candidates and understanding peptide-protein interactions.
Used in Peptide Synthesis:
BOC-3-(1-PYRAZOLYL)-ALA-OH is used as a protected amino acid in the synthesis of peptides. The BOC protecting group prevents unwanted side reactions during the synthesis process, ensuring the formation of the desired peptide sequence. Once the peptide is synthesized, the BOC group can be removed to reveal the free amino group, allowing for further modifications or interactions with other molecules.

InChI:InChI=1/C11H17N3O4/c1-11(2,3)18-10(17)13-8(9(15)16)7-14-6-4-5-12-14/h4-6,8H,7H2,1-3H3,(H,13,17)(H,15,16)/t8-/m0/s1

Upstream product

• 288-13-1 NH-pyrazole 
• 98541-64-1 (S)-3-(tert-butoxycarbonylamino)-oxetan-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2734-48-7 (S)-2-Amino-3-pyrazol-1-yl-propionic acid 
• 18156-75-7 1-trimethylsilylpyrazole 

Downstream Products

• 1416469-43-6 tert-butyl [(2S)-1-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl]piperidin-1-yl}-1-oxo-3-(1H-pyrazol-1-yl)propan-2-yl]carbamate 
• 1416469-42-5 (4aS,8aR)-2-{1-[(2S)-2-amino-3-(1H-pyrazol-1-yl)propanoyl]piperidin-4-yl}-4-(3,4-dimethoxyphenyl)-4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one hydrochloride 
• 1051461-56-3 C₃₈H₄₆N₈O₄S₂ 
• 1562430-37-8 C₃₄H₄₂N₆O₅S 
• 1416467-89-4 4-[5-(cyclopropylmethoxy)-1,3-benzodioxol-4-yl]-N-[(2S)-1-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl]piperidin-1-yl}-1-oxo-3-(1H-pyrazol-1-yl)propan-2-yl]-5H-pyrrolo[3,2-d]pyrimidine-7-carboxamide 
• 1416469-72-1 (4aS,8aR)-2-{1-[(2S)-2-amino-3-(1H-pyrazol-1-yl)propanoyl]piperidin-4-yl}-4-(3,4-dimethoxyphenyl)-4a,5,6,7,8,8a-hexahydrophthalazin-1(2H)-one 
• 136010-47-4 H-3-pyrazol-1-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 
• 136010-44-1 N-(tert-butoxycarbonyl)-3-pyrazol-1-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 

Relevant articles and documents

NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES

The compounds of formula (1) in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.

NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES

The compounds of formula (1), in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS

The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, dyspepsia, irritable bowel syndrome, chemotherapy-induced nausea and vomiting (emesis) and post-operative nausea and vomiting and functional gastrointestinal disorders. In addition, the compounds possess utility for the treatment of diseases and disorders characterized by poor stomach or intestinal absorption, such as short bowel syndrome, celiac disease and cachexia. The compounds also have use for the treatment of inflammatory diseases and disorders of the gastrointestinal tract, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease and pancreatitis. Accordingly, methods of treating such disorders and pharmaceutical compositions including compounds of the present invention are also provided.

Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids

Novel, potent small molecule motilin receptor antagonists are described. These peptidomimetic macrocycles are composed of a tripeptide cyclized backbone-to-backbone with a nonpeptidic tether and bear new unnatural amino acids containing basic side chains.

Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides

A systematic evaluation of structure-absorption relationships using a high throughput intraduodenal rat screening model has led to the delineation of a set of structural parameters that appear to govern bioavailability in a series of peptide-based renin inhibitors. Optimum structures, exemplified by 25 and 41, incorporated a single, solubilizing substituent at the C- or N- terminus combined with a lipophilic P2-site residue. Both inhibitors gave unprecedented plasma drug levels upon intraduodenal administration to monkeys, and the calculated bioavailability for 41 (14 ± 4%) is the highest reported for any peptidic renin inhibitor.